ESMO: AstraZeneca stands by Truqap despite surprise breast cancer flop

[cafead]

via As if a limited initial FDA approval was not bad enough, AstraZeneca’s Truqap has recorded a pivotal trial flop that could raise additional doubts around the first-in-class AKT inhibitor. From AZ’s perspective, a company executive argued the failure was probably a one-off.

article source